Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 10, 2023 · 10-Q · 41 days after period end · 0001493152-23-004150
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$485.42K | -$799.98K | -$403.64K | -$1.87M |
| EPS Diluted | -$0.53 | -$0.02 | -$0.45 | -$1,250.78 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Feb 10, 2023 · 41 d after period end
